Fig. 2

Spheroid Geltrex™ degradation analysis. a Representative software screenshot demonstrating spheroid volume annotation (left panels) and quantification of the tumor volume (graph). UMSCC1 Spheroid volume over a period of 17 days in the presence or absence of TNFα (10 ng/mL) or GM6001 (25 μM). b Representative software screenshot demonstrating Geltrex™ degradation volume in UMSCC1 spheroids over a period of 17 days in the presence or absence of TNFα (10 ng/mL) or GM6001 (25 μM). c MDA-MB-231 spheroid Geltrex™ degradation volume increase over a period of 4 days compared to Day 1 Geltrex™ degradation volume. Volumes are presented as mean per spheroid +/− SEM. Two-way ANOVA followed by Bonferroni post hoc test: * P < 0.01 for GM6001 vs. unstimulated; P < 0.01 TNFα vs. unstimulated; n = 3. d The degradation volume was divided by the spheroid volume and normalized to the first day of measurement. Two-way ANOVA followed by Tukey’s multiple comparison test: *P < 0.01